Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-
2. Korsuva
3. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide
1. 1024828-77-0
2. Cr845
3. Difelikefalin [inn]
4. Mr13a9
5. Cr-845
6. Korsuva
7. Fe202845
8. Na1u919mro
9. Fe-202845
10. Mr-13a9
11. 1024828-77-0 (free Base)
12. 1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-aminopiperidine-4-carboxylic Acid
13. 4-piperidinecarboxylic Acid, N1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-4-amino-
14. 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic Acid
15. Difelikefalin Acetate [jan]
16. Unii-na1u919mro
17. Kapruvia
18. Difelikefalin Tfa
19. Cr 845
20. Difelikefalin (cr845)
21. Difelikefalin (usan/inn)
22. Difelikefalin [usan:inn]
23. Difelikefalin [usan]
24. Seq Id No: 2
25. Difelikefalin [who-dd]
26. Gtpl9044
27. Chembl3989915
28. Schembl10316464
29. Bdbm235785
30. Dtxsid401032896
31. Bcp24752
32. Ex-a5855
33. At30197
34. Db11938
35. Bd177570
36. Hy-17609
37. Cr-845; Fe-202845
38. Cs-0014687
39. D11111
40. Us9359399, 2
41. Q21098992
42. D-phe-d-phe-d-leu-d-lys-[gamma-(4-n-piperidinyl)amino Carboxylic Acid]
43. 4-piperidinecarboylic Acid, 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)-
44. 4-amino-1-(d-phenylalanyl-d-phenylalanyl-d-leucyl-d-lysyl)piperidine-4-carboxylic Acid
45. 4-piperidinecarboxylic Acid, 4-amino-1-((2r)-6-amino-2-(((2r)-2-(((2r)-2-(((2r)-2-amino-1-oxo-3-phenylpropyl)amino)-1-oxo-3-phenylpropyl)amino)-4-methyl-1-oxopentyl)amino)-1-oxohexyl)-
46. N-((2r)-1-(((2r)-1-(((2r)-6-amino-1-(4-amino-4-carboxy-1-piperidinyl)-1-oxo-2-hexanyl)amino)-4-methyl-1-oxo-2-pentanyl)amino)-1-oxo-3-phenyl-2-propanyl)-d-phenylalaninamide
Molecular Weight | 679.8 g/mol |
---|---|
Molecular Formula | C36H53N7O6 |
XLogP3 | -0.6 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 18 |
Exact Mass | 679.40573244 g/mol |
Monoisotopic Mass | 679.40573244 g/mol |
Topological Polar Surface Area | 223 Ų |
Heavy Atom Count | 49 |
Formal Charge | 0 |
Complexity | 1080 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Difelikefalin is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP; uremic pruritus) in adults undergoing hemodialysis.
FDA Label
Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5. 1).
Difelikefalin is administered to patients undergoing hemodialysis for chronic kidney disease (CKD) to prevent and treat the pruritus often associated with CKD. It is administered via bolus intravenous injection at the end of each hemodialysis treatment. As it works on opioid receptors, difelikefalin can cause dizziness, somnolence, and other CNS depressant effects that may impair mental or physical abilities - as such, patients should be advised to avoid operating dangerous machinery until the effect of difelikefalin on that patient is known.
V03AX
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AX - Other therapeutic products
V03AX04 - Difelikefalin
Absorption
Difelikefalin is administered via bolus intravenous injection with each hemodialysis treatment - for this reason, each dose is effectively 100% bioavailable.
Route of Elimination
Following intravenous difelikefalin administration to hemodialysis patients, approximately 11% of the dose was excreted in the urine, 59% in the feces, and 20% in the dialysate.
Volume of Distribution
The mean volume of distribution of difelikefalin is approximately 238 mL/kg.
Clearance
One cycle of hemodialysis reduces difelikefalin plasma concentrations by 70-80% and no detectable drug remains after two cycles.
Difelikefalin is not metabolized to any appreciable extent and is not a substrate for cytochrome P450 enzymes.
The half-life of difelikefalin in hemodialysis patients prior to dialysis ranges between 23 and 31 hours.
Difelikefalin is a synthetic peptide and agonist of kappa opioid receptors (KORs), which have long been known to be involved with the itching sensation (in addition to playing some role in addiction). Endogenous KOR agonists - called dynorphins - have a neuroinhibitory effect on the itching sensation at the spinal cord level and mouse models have shown KOR agonist antipruritic activity when used to treat itching induced by different pruritogens. Although the specifics of the mechanism have yet to be elucidated, the administration of KOR agonists, like difelikefalin, in patients with uremic pruritus has proven an effective means to suppress scratching and improve their quality of life.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Difelikefalin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Difelikefalin, including repackagers and relabelers. The FDA regulates Difelikefalin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Difelikefalin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Difelikefalin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Difelikefalin supplier is an individual or a company that provides Difelikefalin active pharmaceutical ingredient (API) or Difelikefalin finished formulations upon request. The Difelikefalin suppliers may include Difelikefalin API manufacturers, exporters, distributors and traders.
click here to find a list of Difelikefalin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Difelikefalin DMF (Drug Master File) is a document detailing the whole manufacturing process of Difelikefalin active pharmaceutical ingredient (API) in detail. Different forms of Difelikefalin DMFs exist exist since differing nations have different regulations, such as Difelikefalin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Difelikefalin DMF submitted to regulatory agencies in the US is known as a USDMF. Difelikefalin USDMF includes data on Difelikefalin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Difelikefalin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Difelikefalin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Difelikefalin Drug Master File in Japan (Difelikefalin JDMF) empowers Difelikefalin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Difelikefalin JDMF during the approval evaluation for pharmaceutical products. At the time of Difelikefalin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Difelikefalin suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Difelikefalin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Difelikefalin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Difelikefalin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Difelikefalin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Difelikefalin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Difelikefalin suppliers with NDC on PharmaCompass.
Difelikefalin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Difelikefalin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Difelikefalin GMP manufacturer or Difelikefalin GMP API supplier for your needs.
A Difelikefalin CoA (Certificate of Analysis) is a formal document that attests to Difelikefalin's compliance with Difelikefalin specifications and serves as a tool for batch-level quality control.
Difelikefalin CoA mostly includes findings from lab analyses of a specific batch. For each Difelikefalin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Difelikefalin may be tested according to a variety of international standards, such as European Pharmacopoeia (Difelikefalin EP), Difelikefalin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Difelikefalin USP).
LOOKING FOR A SUPPLIER?